Jesse Gelsinger


Also found in: Wikipedia.
A gene therapy patient (1981-1999) who died after a hyperresponse to an engineered adenovirus that caused jaundice, coagulopathy, multiple-organ-system failure and brain death. He thus became the first person to die in a clinical trial for gene therapy
References in periodicals archive ?
Indeed, gene therapy had recently fallen out of favour after 18-year-old Jesse Gelsinger died during an experimental treatment.
Esvelt points to Jesse Gelsinger, an 18-year-old whose death during a 1999 gene therapy trial stifled progress in that field for a decade or more.
The case of Jesse Gelsinger is important to remember in this regard.
That potential for new gene therapy treatments was temporarily derailed after Jesse Gelsinger, an 18-year-old, died in 1999 as a result of treatment in a gene therapy trial.
Most notably, 18-year-old Jesse Gelsinger died in a 1999 clinical trial of a gene therapy treatment for a nonfatal liver disease.
This edition has been revised and updated and includes landmark cases such as Terri Schiavo and Jesse Gelsinger.
Naam is referring to the case of Jesse Gelsinger, an 18-year-old suffering from an inherited liver disorder who died in 1999 when an experimental genetic treatment by University of Pennsylvania researchers caused a traumatic immune reaction.
Arguably, Jesse Gelsinger was motivated by genuine altruism: according to his father, he joined a clinical research study to help save babies who shared his genetic disorder.
Early days of what he called hyped expectations were followed by horror at the death in 1999 of 18-year-old Jesse Gelsinger, who volunteered to participate in a Penn clinical trial of gene therapy for a rare genetic liver disease.
The book begins with a powerful and heartbreaking account of the Jesse Gelsinger tragedy, written with balance and reserve by Jesse's father, Paul.